Novartis Zometa
Executive Summary
Serum creatinine data from Novartis' ongoing zolendronate trials for the treatment of bone metastases is among FDA's requests in a Sept. 21 "approvable" letter for Zometa in hypercalcemia of malignancy. In June, Novartis eliminated the 8 mg arm of the ongoing studies after elevated serum creatinine levels were detected in some patients (1"The Pink Sheet" June 26, p. 21). A priority review user fee goal date of June 21 was extended three months at that time. The bone metastases studies are scheduled to be complete within the first half of 2001
You may also be interested in...
Novartis Zometa Acquisition Cost Of $713 Per Dose Is 2% Higher Than Aredia
Novartis' hypercalcemia therapy Zometa will be available at the wholesale acquisition cost of $713.65 per 4 mg dose. Shipments to wholesalers are expected to begin during the week of Aug. 27.
Novartis Zometa Acquisition Cost Of $713 Per Dose Is 2% Higher Than Aredia
Novartis' hypercalcemia therapy Zometa will be available at the wholesale acquisition cost of $713.65 per 4 mg dose. Shipments to wholesalers are expected to begin during the week of Aug. 27.
Novartis Alzheimer's Drug Exelon Captures 25% Of New Rxs In U.S.
Novartis is finding room for new Rx growth in the Alzheimer's treatment category, where Exelon has nearly doubled its share of new Rxs in the past two months.